Otezla Archives -

Bristol-Myers Squibb’s deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in

BMS scores first approval for psoriasis therapy Sotyktu

https://pharmaphorum.com/news/bms-scores-first-approval-for-psoriasis-therapy-sotyktu/

News/ News/ Sales and Marketing

Amgen builds Otezla’s psoriasis label as rival BMS looms large

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, Otezla, psoriasis, sales & marketing 0 Comment

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it

Amgen builds Otezla’s psoriasis label as rival BMS looms large

https://pharmaphorum.com/news/amgen-builds-otezlas-psoriasis-label-as-rival-bms-looms-large/

Market Access/ News/ News

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, Immunology and inflammation, Otezla, psoriasis 0 Comment

The FDA has kicked off its review of Bristol-Myers Squibb’s psoriasis therapy deucravacitinib, setting an action date of

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

https://pharmaphorum.com/news/fda-sets-sept-review-date-for-bms-psoriasis-drug-deucravacitinib/

News/ News/ R&D

Failed IBD trial dents confidence in BMS’ deucravacitinib

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, inflammatory bowel disease, Otezla, ulcerative colitis 0 Comment

Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD)

Failed IBD trial dents confidence in BMS’ deucravacitinib

https://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/

News/ News/ Sales and Marketing

Dermavant raises $200m to ease launch of Otezla rival tapinarof

Phil Taylor Amgen, dermatology, Dermavant, financing, Otezla, psoriasis, tapinarof 0 Comment

Dermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches

Dermavant raises $200m to ease launch of Otezla rival tapinarof

https://pharmaphorum.com/news/dermavant-raises-200m-to-ease-launch-of-otezla-rival-tapinarof/

News/ News/ R&D

Amgen to test psoriasis pill Otezla in COVID-19

Richard Staines Amgen, coronavirus, COVID-19, Otezla, R&D 0 Comment

Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by

Amgen to test psoriasis pill Otezla in COVID-19

https://pharmaphorum.com/news/amgen-to-test-psoriasis-pill-otezla-in-covid-19/

News/ News/ Sales and Marketing

Amgen stumps up $13.4bn to claim Otezla from Celgene

Phil Taylor Bristol-Myers Squibb, Celgene, immunology, M&A, Otezla, psoriasis 0 Comment

Celgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen

Amgen stumps up $13.4bn to claim Otezla from Celgene

https://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/

News/ News/ Patients

Celgene gets new approval for soon-to-be-shed Otezla

Phil Taylor Celgene, inflammation, Otezla, rare disease 0 Comment

Celgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial

Celgene gets new approval for soon-to-be-shed Otezla

https://pharmaphorum.com/news/celgene-gets-new-approval-for-soon-to-be-shed-otezla/

News/ News

BMS will shed Otezla to push Celgene takeover through

Phil Taylor Bristol-Myers Squibb, Celgene, Mergers and acquisitions, Otezla, psoriasis 0 Comment

Bristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion

BMS will shed Otezla to push Celgene takeover through

https://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/

Trending

Otezla

Login